Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023

Biomica Ltd., a biopharmaceutical company under Evogene Ltd. (NASDAQ: EVGN), will participate in the J.P.

Rhea-AI Summary

Biomica Ltd., a biopharmaceutical company under Evogene Ltd. (NASDAQ: EVGN), will participate in the J.P. Morgan Healthcare Week from January 9 to 11, 2023, in San Francisco. This follows a successful financing round of $20 million led by Shanghai Healthcare Capital. Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings.

Biomica focuses on developing microbiome-based therapeutics for antibiotic resistance, immuno-oncology, and gastrointestinal disorders, utilizing a unique Computational Predictive Biology platform.

Argus Session date unavailable

-5.18% session move Open Argus

Details

News Market Reaction – EVGN

The recorded move for EVGN in the trading session of this news was -5.18%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, Dec. 28, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco. The conference is one of the industry's largest conferences of the year.

 

 

This follows Biomica's recent successful financing round of $20 million, led by Shanghai Healthcare Capital, a leading Chinese private equity fund.

In attendance will be Dr. Elran Haber, CEO of Biomica, throughout the week from Monday, January 9 until Wednesday, January 11, 2023.

Dr. Haber will be available for one-on-one meetings throughout the week, and those interested should be in touch with Biomica's investor or public relations team.

About Biomica

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN). For more information, please visit www.biomicamed.com.

Logo - https://mma.prnewswire.com/media/1974949/Biomica_Logo.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

 

 

Evogene Investor Contact:
Kenny Green
kenny.green@evogene.com
+1 (212) 378 8040

View original content:https://www.prnewswire.com/news-releases/biomica-ceo-to-attend-the-jp-morgan-healthcare-week-in-san-francisco-between-january-9-11-2023-301710529.html

SOURCE Biomica Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event will Biomica Ltd. attend in January 2023?

Biomica Ltd. will attend the J.P. Morgan Healthcare Week in San Francisco from January 9 to 11, 2023.

Who is the CEO of Biomica attending the J.P. Morgan Healthcare Week?

Dr. Elran Haber is the CEO of Biomica attending the J.P. Morgan Healthcare Week.

How much did Biomica recently raise in financing?

Biomica raised $20 million in a recent financing round led by Shanghai Healthcare Capital.

What type of therapeutics is Biomica developing?

Biomica is developing microbiome-based therapeutics targeting antibiotic resistance, immuno-oncology, and gastrointestinal disorders.

What stock symbol is associated with Evogene Ltd.?

The stock symbol for Evogene Ltd. is EVGN.